Sanofi partnered with AI-driven biotech firm Earendil Labs to discover and develop bispecific antibodies for autoimmune and inflammatory diseases, with a deal valued at up to $2.56 billion14
Earendil will use its AI-powered discovery platform combining predictive protein modeling and high-throughput experimental validation to identify bispecific antibody candidates, while Sanofi leads clinical development and worldwide commercialization12
Earendil will receive $160 million in upfront and near-term milestone payments, plus tiered royalties reaching up to low double-digit percentages on net product sales14
The collaboration was announced in early January 2026 and marks the second partnership between Sanofi and Earendil, following an April 2025 deal for bispecific antibodies HXN-1002 and HXN-100347
This deal reflects Sanofi's strategic shift toward autoimmune disorders, oncology, and vaccines, as the company seeks next-generation molecular formats like bispecific antibodies to address limitations of existing single-target biologics4
Sources:
1. https://www.bioxconomy.com/partnering/sanofi-inks-autoimmune-bispecific-deal-with-ai-firm-worth-up-to-2-56bn
2. https://www.biopharmaboardroom.com/news/87/4201/earendil-labs-and-sanofi-forge-strategic-collaboration-to-advance-ai-discovered-bispecific-therapies-for-autoimmune-diseases.html
4. https://www.vcbeathealth.com/article/2331
7. https://www.bioworld.com/articles/727792-ai-drug-discovery-brings-2b-sanofi-deal-to-1-year-old-earendil